3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
83
Pancreatic Neoplasms
33
Stomach Neoplasms
32
Rectal Neoplasms
23
Colonic Neoplasms
22
Neoplasms
20
Neoplasm Metastasis
19
Esophageal Neoplasms
16
Cholangiocarcinoma
14
Adenocarcinoma Of Esophagus
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Carcinoma, Non-Small-Cell Lung
12
Burkitt Lymphoma
12
Biliary Tract Neoplasms
12
Adenocarcinoma
11
Gastrointestinal Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Ovarian Neoplasms
6
Leukemia, Biphenotypic, Acute
5
Gallbladder Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Endometrial Neoplasms
5
Advanced Solid Tumors
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lung Neoplasms
4
Leukemia
4
Carcinoma, Renal Cell
4
Appendiceal Neoplasms
4
Urinary Bladder Neoplasms
3
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Leucovorin
×
1 year
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled